Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Dapagliflozin and Telmisartan in T2DM and Essential Hypertension
NCT06647745Phase 3Recruiting
- Sponsor
- THPharm
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin and telmisartan in type 2 diabetes mellitus (T2DM) and essential hypertension (4 arms), sponsored by THPharm. Primary endpoints: Changes in Hemoglobin A1c at 12 weeks and Changes in Mean Sitting Systolic Blood Pressure at 12 weeks. Started Apr 2025; status: recruiting.
02
Drugs
dapagliflozintelmisartan
03
Conditions
type 2 diabetes mellitus (T2DM)essential hypertension
Beyond the preview
Go deeper on NCT06647745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647745.